Theseus Pharmaceuticals is a biopharmaceutical company that develops specialized cancer treatments, including THE-630 which is currently in Phase I research for gastrointestinal stromal tumors. The company also creates treatments that target drug resistance mutations in oncogenes, which often cause cancer. Based in Cambridge, Massachusetts, Theseus Pharmaceuticals was established in 2017.